Uncategorized
IMPACT: No difference in number of injections with or without squalamine lactate for wet AMD
No meaningful difference was found in mean number of injections of squalamine lactate ophthalmic solution combined with Lucentis compared with Lucentis monotherapy for treatment of wet age-related macular degeneration, according to topline results of the IMPACT study released by Ohr Pharmaceutical.Mean number of injections was the primary endpoint in the phase 2 study, a 9-month clinical trial evaluating the safety and efficacy of OHR-102 (0.2% squalamine lactate ophthalmic solution) plus as-needed Lucentis (ranibizumab, Genentech) combination therapy for neovascular AMD.